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The noninvasive measurement of functional β-cell mass would be clinically valuable for 
monitoring the progression of type 1 and type 2 diabetes, as well as the viability of transplanted 
insulin-producing cells. Although previous work employing magnetic resonance imaging has shown 
promise for functional β-cell mass determination through voltage-dependent Ca
2+
 channel (VDCC)-
mediated internalization of Mn
2+
, the clinical utility of this technique is limited by the cytotoxic 
levels of Mn
2+
 contrast agent. Here, we show that positron emission tomography (PET) is 
advantageous for determining functional β-cell mass using 
52
Mn
2+
 (t1/2: 5.6 d). We investigated the 
whole-body distribution of 
52
Mn
2+
 in healthy adult mice by dynamic and static PET imaging. 
Pancreatic VDCC uptake of 
52
Mn
2+
 was successfully manipulated pharmacologically in vitro and in 
vivo using glucose, nifedipine (VDCC blocker), the sulfonylureas tolbutamide and glibenclamide 
(KATP channel blockers), and diazoxide (KATP channel opener). In a mouse model of streptozotocin 
(STZ)-induced type 1 diabetes, 
52
Mn
2+
 uptake in the pancreas was distinguished from healthy 
controls in parallel with classic histological quantification of β-cell mass from pancreatic sections. 
52
Mn
2+
-PET also reported the expected increase in functional β-cell mass in the ob/ob model of pre-
type 2 diabetes, a result corroborated by histological β-cell mass measurements and live-cell 
imaging of β-cell Ca
2+
 oscillations. These results indicate that 
52
Mn
2+
-PET is a sensitive new tool for 
the non-invasive assessment of functional β-cell mass.  
 
Type 1 and type 2 diabetes, while arising from different etiologies, are each associated with the 
functional loss of insulin-secreting β-cells and can lead to life-threatening complications such as 
cardiovascular disease and neuropathy (1). As such, a variety of therapeutics are being pursued that aim to 
preserve, expand, or replace β-cells. An imaging modality capable of monitoring functional β-cell mass in 
vivo as well as the viability of islet- or stem cell-derived β-cell transplants would therefore be invaluable 
to future therapeutic investigations. 
Human pancreatic islets occupy approximately 4.5% of the pancreas volume, and are composed 
of a mixture of β, α, γ, δ, and ε cells (2; 3). As individual islets vary in size from 25 to 400 µm in diameter 
(3-5) and are non-uniformly distributed throughout the pancreas, quantification is challenging through 
noninvasive anatomical imaging techniques such as magnetic resonance imaging (MRI) or computed 
tomography (CT) (6). Alternatively, positron emission tomography (PET) is a technique that involves 
quantifying the in vivo distribution of a biologically relevant moiety by tracking a positron-emitting 
radioisotope. Compared with MRI and CT, PET has significantly greater imaging sensitivity and 
inherently probes physiology rather than anatomy (7), which may prove useful in the clinical 
quantification of functional β-cell mass.  
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Mn
2+
, in a behavior that mimics Ca
2+
, is freely transported through voltage-dependent Ca
2+
 
channels (VDCC) (8; 9). Since VDCC activation is required for the release of insulin from β-cells, Mn
2+
 
has been proposed as a molecular imaging agent for probing β-cell function and mass using Mn
2+
-
enhanced magnetic resonance imaging (MEMRI) (10-15). However, this technique is limited by 
significant cellular toxicity and the slow biological clearance of Mn
2+
, which prevents the possibility of 
repeated administration (9; 16). Since PET has several orders of magnitude higher sensitivity than MRI, 
the objective of this work was to assess the feasibility of using PET to probe β-cell mass and function.  
 Herein, we take advantage of the exceptional sensitivity and quantitation capability of PET and 
the availability of radiomanganese (
52
Mn
2+
) to noninvasively image functional β-cell mass in vivo. When 
intravenously injected in mice, 
52
Mn
2+
 (t1/2: 5.6 d) showed a rapid accumulation in the mouse pancreas 
that was sensitive to glucose and pharmacologic manipulation of VDCC. We also explored the potential 
of 
52
Mn
2+
-PET to detect changes in functional β-cell mass in mouse models of type 1 and type 2 diabetes. 
Overall, our results point to the significant potential for radiomanganese to overcome several limitations 
of other β-cell imaging agents and potentially become a method of choice for studying β-cell physiology 
noninvasively. 
 
RESEARCH DESIGN AND METHODS  
52
Mn
2+
-PET Imaging  
Aliquots of the buffered 
52
Mn
2+
 solution (0.01M NaOAc, pH 6.5) were diluted to the desired injection 
volume (~200 µl) with phosphate-buffered saline (PBS), typically 2 – 4 MBq (approximately 50 – 100 
µCi) per subject. The acquisition of PET images was performed with an Inveon µPET/µCT scanner 
(Siemens Preclinical Solutions). To study the biodistribution and clearance of 
52
Mn
2+
 in the mouse, 3.7 
MBq (100 µCi) of 
52
Mn
2+
 was IV injected into female ICR mice. Due to the long decay half-life of 
52
Mn 
(t1/2: 5.6 d), PET scans were recorded at multiple time-points between 1 h and 13 days post-injection of 
the radiotracer. Before each scan, mice were anesthetized with isoflurane (4% induction; 1% 
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maintenance) and placed in the scanner in the prone position. 30-40 × 10
6
 coincidence events per mouse 
static PET scans were acquired (time window, 3.432 ns; energy window, 350−650 keV) and the PET 
images were reconstructed in Inveon Acquisition Workplace (Siemens Preclinical Solutions) workstation 
using a non-scatter-corrected three-dimensional Ordered Subset Expectation Optimization/Maximum a 
Posteriori (OSEM3D/MAP) algorithm. Region-of-interest (ROI) analysis was performed after organs 
were manually delineated on the PET images. Tissue 
52
Mn
2+
 uptake values are reported as standardized 
uptake value (SUV), which is normalized to whole body radiomanganese concentration to account for 
weight disparities between animal models. Percentage injected dose per gram of tissue (%ID/g) is also 
reported in the Supplementary Material (Table S6-S9). To acquire dynamic PET scans, mice were 
anesthetized with isoflurane and the lateral tail vein was catheterized. Simultaneous with the 
administration of approximately 1.7 MBq (~50 µCi) of 
52
Mn
2+
 as a fast IV bolus, one-hour scans were 
recorded and list-mode files were binned into 46 frames (12×5 s, 6×10 s, 6×30 s, 10×60 s, 6×150 s, 6×300 
s) and the images reconstructed using the OSEM3D/MAP algorithm. For comparison, 1.7 MBq (50 µCi) 
of 
52
Mn
2+
 was continuously infused with a syringe pump (KD Scientific, Model 780100) during the first 
30 min of a 60 min experiment, and list-mode files were binned into 30 frames (2 min each) and 
reconstructed using the OSEM3D/MAP algorithm.  
Effect of Pharmacological VDCC Manipulation on 
52
Mn
2+
 Uptake In Vivo 
Pancreatic 
52
Mn
2+
 uptake was stimulated using glucose and glibenclamide (Tocris Biosciences), which is 
known to promote insulin release in β-cells via blockade of ATP-sensitive K
+
 channels (KATP). Mice were 
injected IP with 100 µL of 1 g/kg glucose, or glucose plus 5 mg/kg glibenclamide in PBS, 15 min before 
the IV injection of 0.74 – 1.85 MBq (20 – 50 µCi) of 
52
Mn
2+
. VDCC blockade was achieved via IP 
injection of 20 mg/kg nifedipine (MP Biomedicals) dissolved in dimethyl sulfoxide. To activate KATP 
channels, mice received an IP injection of 20 mg/kg diazoxide (Tocris Biosciences) in PBS, a clinically 
used KATP agonist, 15 min before injection of 0.74 MBq (20 µCi) of 
52
Mn
2+
. Whole-body PET scans were 
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acquired 1 h after the injection of the radiotracer, after which ex vivo biodistribution analysis was 
performed.  
52
Mn
2+
-PET Studies in a Type 1 Diabetes Model 
Type 1 diabetes was induced in female ICR mice via a single IP injection of 180 mg/kg streptozotocin 
(STZ; MP Biomedical), a toxin that selectively destroys pancreatic β-cells (17). The injectable STZ 
solution (12.5 mg/mL) was prepared fresh in PBS. The weight of each mouse was measured daily, and 
blood glucose levels were recorded every other day with a glucometer (TRUEresult, Trividia Health Inc.) 
using blood samples collected from the tail vein. Mice were considered diabetic after two consecutive 
blood glucose readings above 250 mg/dL and were used for 
52
Mn
2+
-PET imaging studies one week after 
the injection of STZ. To evaluate 
52
Mn
2+
 pancreatic uptake on diabetic mice, 0.74 MBq (20 µCi) of 
radioactivity was administered IV and static PET images were recorded 1 h after administration of the 
tracer. Ex vivo biodistribution was carried out following PET acquisition. 
52
Mn
2+
-PET Studies in a Pre-Type 2 Diabetes Model 
Pancreatic uptake of 
52
Mn
2+
 in was measured in 10-week-old wildtype and ob/ob mice on the C57BL/6J 
background. For PET imaging, 0.74 MBq (20 µCi) of 
52
Mn
2+
 was IV injected 1 h prior to PET scan 
acquisition. 
52
Mn
2+
 accumulation in the pancreas and other organs of interest was also quantified by ex 
vivo biodistribution analysis.  
Additional Materials and Methods 
Animal studies were conducted under the approval of UW Institutional Animal Care and Use Committee. 
Detailed information on animal models, isotope production, ex vivo biodistribution, islet isolation and 
imaging, and β-cell mass measurement is provided as supplementary information. 
 
RESULTS 
In vivo whole-body PET and biodistribution of 
52
Mn
2+
 in normal mice 
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The in vivo biodistribution of 
52
Mn
2+
 was investigated noninvasively with PET and ex vivo 
gamma counting. Figure 1A shows coronal planes intersecting the pancreas of ICR mice, in PET scans 
acquired between 1 hour and 13 days after IV injection of 3.7 MBq (100 µCi) of 
52
Mn
2+
. A rapid and 
prominent accumulation of 
52
Mn
2+
 was observed in the pancreas, kidneys, liver, heart, and salivary glands 
(5.13 ± 0.38, 5.13 ± 0.02, 3.27 ± 0.36, 2.11 ± 0.20, and 2.30 ± 0.26 SUV at 1 h post-injection, 
respectively; n=3; Figure 1B). In the subsequent time points during the longitudinal study, 
52
Mn
2+
 uptake 
gradually declined in all organs except the salivary gland where uptake remained stable at a SUV of ~3 
(Figure 1B, Table S1). 
52
Mn
2+
 uptake in the pancreas, which was highest at 1 h post-injection, was 
notably higher than that in the liver and kidneys at all time points. Such favorable pancreas-to-normal 
organ contrast ratios, which peaked at about 3 days after 
52
Mn
2+
 administration, facilitated an easy 
delineation of the pancreas (Figure S1). Uptake in the muscle was very low and had little variation during 
the study. Ex vivo biodistribution was performed after the last PET scan 13 days post-injection, 
confirming a marked accumulation of 
52
Mn
2+
 in the salivary gland, pancreas, kidneys, and to a lesser 
extent, the heart and liver (Figure 1C, Table S2). Other organs including the brain, lungs, bones, 
intestines, stomach, and spleen displayed low 
52
Mn
2+
 uptake, typically less than 0.5 SUV.  
Because the whole-body distribution of 
52
Mn
2+
 occurred largely within the first hour after IV 
administration (Figure 1), a dynamic PET study was designed to investigate the 
52
Mn
2+
 kinetics during 
this time. Figure 2 shows the time-activity curves (TACs) resulting from ROI analysis of the dynamic 
PET data corresponding to the pancreas, liver, kidneys, heart, salivary gland, and muscle under two IV 
administration regimes: rapid bolus injection, and 30 min continuous infusion. The analysis of the 
myocardial TAC revealed extremely fast blood extraction kinetics with a blood circulation half-life of 
10.7 ± 3.5 s in mice administered a rapid IV 
52
Mn
2+
 bolus. Consequently, 
52
Mn
2+
 uptake was stabilized in 
the organs of interests within 5 min post-injection. A residual radioactivity of 2.60 ± 0.41 SUV was 
observed in the heart at 1 h post-injection, which was consistent with the specific uptake of Mn
2+
 ions by 
myocardial tissue. Compared to the static 1 h post-injection PET scans (Figure 1), similar 
52
Mn
2+
 uptake 
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values were observed following rapid bolus injection in the heart (2.11 ± 0.20 vs. 2.60 ± 0.41 SUV) and 
muscle (0.38 ± 0.03 vs 0.16 ± 0.02 SUV), while liver (3.27 ± 0.34 vs. 5.16 ± 1.46 SUV) and kidneys 
(5.13 ± 0.02 vs. 7.81 ± 0.51 SUV) were much higher at the end of the dynamic scan after a rapid IV 
52
Mn
2+
 bolus. Interestingly, a ~50% reduction in pancreatic uptake from 5.13 ± 0.38 to 2.74 ± 0.59 SUV 
was observed in the dynamic studies. 
As clearly depicted in Figure 2 (red curves), continuous infusion of 
52
Mn
2+
 over a 30-min time 
period resulted in a linear ramping in organ radioactivity, followed by an immediate plateau upon infusion 
termination that persisted for the remainder of the experiment. This method highlights the rapid 
distribution kinetics of 
52
Mn
2+
 and the comparable results obtained by either rapid bolus or continuous 
infusion of 
52
Mn
2+
. Only the kidney displayed higher radioactivity at 1 h post-injection in mice 
administered the rapid bolus vs. mice receiving continuous 
52
Mn
2+
 infusion, 7.81 ± 0.51 vs. 5.14 ± 1.21 
SUV, respectively (n=4). During the continuous infusion regime, pancreas reached an uptake of 3.44 ± 
0.69 SUV which, similar to the rapid bolus injection, was also significantly lower than that in the static 
PET scans at 1 h post-injection (5.13 ± 0.38 SUV).  
Previous reports have shown that many volatile anesthetics, including isoflurane, impair insulin 
secretion by inhibiting the glucose-dependent inactivation of KATP channels (18; 19). Plausibly, the 
observed decrease in pancreatic uptake of 
52
Mn
2+ 
resulted from mice being anesthetized through the full 
extent of the studies during the dynamic PET scans. To investigate the impact of isoflurane anesthesia on 
pancreatic uptake of 
52
Mn
2+
, 1 h post-injection biodistribution experiments were performed under 
different administration conditions in either anesthetized (1% isoflurane) or awake mice. Figure S2 
shows that isoflurane significantly inhibited the accumulation of 
52
Mn
2+
 in the pancreas regardless of the 
administration regime (rapid bolus vs infusion) or glucose stimulation, suggesting that isoflurane indeed 
acts as an indirect VDCC inhibitor upstream of KATP channel closure. 
Uptake of 
52
Mn
2+
 in isolated islets 
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To corroborate the mechanism of 
52
Mn
2+
 uptake in the pancreas and its dependence on VDCC, an 
ex vivo 
52
Mn
2+
 uptake study was performed in islets isolated from ob/ob mice (to take advantage of the 2-
fold greater islet yield vs. wildtype mice). Due to the similarities between Mn
2+
 and Ca
2+
 ions, Mn
2+
 
uptake by β-cells occurs via influx through VDCC (Figure 3A) (20; 21). Isolated islets were incubated 
with 0.37 MBq (10 µCi) of 
52
Mn
2+
 under several conditions that stimulate/inhibit VDCC (Figure 3B). 
52
Mn
2+
 was readily taken up by islets, even in the presence of low (1 mM) glucose, as expected for the 
high basal Ca
2+
 and insulin secretion reported for ob/ob β-cells (22). 
52
Mn
2+
 uptake was significantly 
enhanced (P < 0.05) when the islets were stimulated with 10 mM glucose. Importantly, 
52
Mn
2+
 uptake 
was completely blocked by the further application of diazoxide (50 µM), which inhibits the opening of 
VDCC via activation of KATP channels. As expected for the clearance of intracellular Ca
2+
 in response to 
diazoxide (23), intracellular 
52
Mn
2+
 fell below the basal level. Conversely, glucose administered with the 
KATP channel blocker tolbutamide (250 µM) resulted in significantly higher 
52
Mn
2+
 retention than glucose 
alone. Taken together, these experiments demonstrate that pancreatic islet uptake of 
52
Mn
2+ 
depends on 
the activity of β-cell VDCC. 
Pharmacological manipulation of 
52
Mn
2+
 pancreatic uptake in vivo 
To verify the specificity of 
52
Mn
2+
 accretion in the pancreas noninvasively using PET imaging, 
52
Mn
2+
 pancreatic uptake was pharmacologically manipulated in vivo through the inhibition or stimulation 
of VDCC. In line with the in vitro results, inhibition of VDCC by direct blockade with nifedipine, or 
activation of KATP with diazoxide resulted in a significant (P < 0.0001) abrogation of the PET signal 
within the pancreas. Figure 4A shows coronal PET slices of the pancreas of ICR mice receiving 20 
mg/kg IP injections of nifedipine or diazoxide, 10-15 min before the administration of an intravenous 
52
Mn
2+
 bolus. Compared to the control group, a clear decrease in pancreatic PET signal was observed 1 h 
following injection of 
52
Mn
2+
. PET quantification revealed a 44% (5.13 ± 0.36 vs. 2.85 ± 0.92 SUV) and 
54% (5.13 ± 0.36 vs. 2.36 ± 0.61 SUV) decline in 
52
Mn
2+
 uptake in groups administered diazoxide and 
nifedipine, respectively (Figure 4B and C). The remnant pancreatic signal suggests that IP drug injection 
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of resulted in the incomplete blockade of VDCC, or more likely, that some 
52
Mn
2+
 uptake is independent 
of VDCC (8). On the contrary, mice administered glibenclamide (5 mg/kg) exhibited a significant 
enhancement in pancreatic uptake of 
52
Mn
2+
. The distribution of 
52
Mn
2+ 
in other organs of interest 
including the heart, liver, kidneys, spleen and salivary gland remained largely unaltered among groups 
(Table S3 and S4). These results demonstrate the potential of 
52
Mn
2+
 PET imaging to noninvasively 
detect changes in functional β-cell mass. 
52
Mn
2+
 uptake in mouse models of type 1 and type 2 diabetes 
We further investigated the correlation between pancreatic 
52
Mn
2+
 uptake and functional β-cell 
mass in a murine model of type 1 diabetes. Diabetes was induced in female ICR mice via a single 
streptozotocin (STZ) injection (180 mg/kg). Four days after injection (Figure 5A), mice presented signs 
of hyperglycemia (blood glucose > 250 mg/dL) and weight loss that indicated a diabetic status. As seen in 
the PET images (Figure 5B), 
52
Mn
2+
 accumulation within the pancreas of diabetic mice was reduced by 
~60%, from 5.13 ± 0.38 SUV (n=3) in normal mice to 2.04 ± 0.81 SUV (n=3) in diabetic mice (P < 
0.0001) (Figure 5C, Table S3 and S4). Ex vivo biodistribution analysis corroborated a very similar 
(58%) decrease in pancreatic accumulation of 
52
Mn
2+
 (Figure 5D).  To compare 
52
Mn
2+
-PET imaging 
with a direct histological assessment of β-cell mass, 3 pancreata per treatment group were weighed, 
sectioned, and immunostained for insulin. On average, β-cell mass in the STZ-treated mice fell by ~70% 
when compared to the sham-injected ICR mice (Figure 5E), in good agreement with the 
52
Mn
2+ 
PET data. 
52
Mn
2+
-PET imaging studies were also performed in C57BL/6J mice carrying the lep
ob 
(ob/ob) 
spontaneous mutation that results in obesity and pre-type 2 diabetes. In this case, 
52
Mn
2+
 accumulation in 
the pancreas of ob/ob mice was significantly (P < 0.001) higher than the wildtype C57BL/6J mice 
(Figure 6A). 1 h after administration of 
52
Mn
2+
 (n=3), pancreatic uptake was 4.89 ± 0.68 SUV in wildtype 
C57BL/6J mice and 7.27 ± 1.03 SUV in ob/ob mice (Figure 6B). Ex vivo biodistribution analysis 
corroborated the statistically significant differences in pancreatic SUV between the groups (P < 0.001; 
Figure S3 and Table S5). Uptake in the liver and salivary gland was very similar in ob/ob and wildtype 
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animals with SUVs of 3.68 ± 0.25 vs. 3.40 ± 0.73 and 3.11 ± 1.05 vs. 2.40 ± 0.20, respectively. In 
agreement with 
52
Mn
2+
-PET imaging, post hoc analysis of insulin-stained pancreatic sections showed a 
significantly (P < 0.05, n=3) increased β-cell mass in ob/ob mice relative to controls (Figure 6C). We 
also observed that ob/ob islet Ca
2+
 levels, which oscillate in response to glucose stimulation (Figure 6D), 
were strongly left-shifted in their glucose dependence relative to controls (Figures 6E, 6F), in agreement 
with the in vivo 
52
Mn
2+
-PET results and prior functional studies (22). Notably, in contrast to the 
experiments in Figure 4, where pharmacologic VDCC manipulation was used to strictly define functional 
β-cell mass, the experiments in Figures 5 and 6 show that basal 
52
Mn
2+
 uptake (measured in the absence 
of exogenous glucose or VDCC inhibitors) remains heavily dependent on changes in β-cell mass. Both 
approaches, when applied clinically, are likely to yield useful information. 
DISCUSSION 
The loss of functional β-cell mass is a cornerstone of both type 1 and type 2 diabetes (24). Here, 
we leverage the ability of β-cells to sequester divalent metal ions (e.g. Ca
2+
, Mn
2+
, Zn
2+
, and Co
2+
), which 
is essential to the production and release of insulin. While β-cell function has been widely investigated 
based on the measurement of Ca
2+
 currents in vitro (25), little progress has been achieved in exploring 
divalent metal intake for measurement of functional β-cell mass in vivo. Part of this is due to the lack of 
effective methods to track the distribution of most of these metals. Fortunately, 
52
Mn
2+
 has both magnetic 
and nuclear properties that facilitate its noninvasive detection by MRI, and with greater sensitivity, PET. 
In the present work, we report the use of radioactive manganese for noninvasive PET imaging of the 
mouse pancreas. When injected intravenously, 
52
Mn
2+
 accumulated significantly into pancreatic tissue 
with exceptionally fast blood extraction kinetics. 
52
Mn
2+
 uptake in the pancreas, which peaked within 
minutes following administration in healthy mice, was on the order of 5-6 SUV with slow clearance half-
life of approximately 8 days. Our results demonstrate that in vivo measurements of functional β-cell mass 
by 
52
Mn
2+
-PET offers complementary information to existing β-cell function assays that lack spatial 
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information (e.g. measurement of c-peptide release), as well as measures of β-cell mass that cannot 
predict β-cell function (e.g. PET imaging with radiolabeled exendin-4).  
A key finding of our work was that 50-60% of the observed pancreatic radioactivity resulted from 
the specific uptake of 
52
Mn
2+
 through VDCC, implicating β-cells. By pharmacologically manipulating the 
mechanism of VDCC in isolated islets, we were able to correlate the uptake of radioactive 
52
Mn
2+
 with 
Ca
2+
 uptake. This agrees with other in vitro studies using non-radioactive Mn
2+
 that reported a correlation 
between Mn
2+
 uptake and changes in β-cell functional capacity arising from the triggering pathway (14; 
15; 26). Similarly, in vivo studies demonstrated that chemical inhibition of VDCC, using nifedipine or 
diazoxide, resulted in a drastic decline in the accumulation of 
52
Mn
2+
 within the pancreas. In addition, the 
stimulation of VDCC with glucose and glibenclamide led to an increase in 
52
Mn
2+
 uptake in the pancreas. 
Overall, our results indicated that the 
52
Mn
2+
 uptake observed in the pancreas was largely mediated by and 
dependent on the functional β-cell mass, keeping in mind that 
52
Mn
2+
-PET would be blind to defects in 
the neurohormonal amplifying pathways of insulin secretion, which are largely VDCC-independent (27).  
Our next question was if this method was sensitive enough to detect changes in functional β-cell 
mass that occur during diabetes progression and disease. First, we employed an experimental animal 
model of STZ-induced type 1 diabetes, which showed a ~60% reduction in the pancreatic accumulation of 
52
Mn
2+
, while uptake in other organs remained unaltered. Direct measurements of β-cell mass by 
histology showed a comparable decline (~70%), indicating the capability of 
52
Mn
2+
-PET imaging for 
revealing extreme cases of β-cell loss. Equally relevant results were observed in the obese mouse (ob/ob) 
model of pre-type 2 diabetes, where significant (P < 0.0001) enhancement in pancreatic uptake of 
52
Mn
2+ 
was observed. These results agree with previous reports showing that ob/ob mice do not progress to 
type 2 diabetes (28; 29), but rather present markedly higher functional β-cell mass compared with 
wildtype mice at 10 weeks of age, as assessed by histology and live-cell Ca
2+
 imaging. Probing the 
gradual gain/loss of functional β-cell mass using 
52
Mn
2+
 (t1/2= 5.6 d) was not feasible due to its long 
radioactive half-life. Rather than trying to account for the remnant 
52
Mn radioactivity in the pancreas, 
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longitudinal studies would benefit from the use of the shorter-lived 
51
Mn (t1/2: 45.6 min), which would 
facilitate regular monitoring of variations in functional β-cell mass without the interference of remnant 
radioactivity. This is the subject of our future work. 
As there can be significant changes in β-cell function long before changes in anatomical mass are 
observed (30-32), it is advantageous that the relative uptake of 
52/51
Mn
2+
 in vivo depends on the functional 
β-cell mass. This ability has the potential to shed light on the rate of functional β-cell mass decline in 
asymptomatic type 1 diabetic patients, as well as the survival of β-cell transplants, including stem cell-
derived β-cells. Whether 
51/52
Mn
2+
-PET is capable of measuring very subtle changes in this parameter is 
the pivotal question to its clinical significance. The diffusion of Mn
2+
 through β-cell VDCCs depends on 
their activation by glucose or drug-based stimulation. This has been shown here through in vitro and in 
vivo functional suppression and enhancement studies. For a given state of glucose activation, the amount 
of Mn
2+
 cellular internalization by the pancreas is partly controlled by the number of available VDCCs, 
which should be proportional to functional β-cell mass. However, accurate quantification of functional β-
cell mass will require subtraction of nonspecific exocrine pancreas uptake of the radiotracer. For this 
reason, the 
52
Mn
2+
-PET measurements in ob/ob mice underestimate the predicted effect on functional β-
cell mass. Calibration may be accomplished through pharmacological manipulation to acutely suppress 
VDCC-mediated uptake of 
52
Mn
2+ 
using nifedipine, diazoxide, or other suppressing agents. Though, same 
subject calibration will require the implementation of either back-to-back PET scans using the shorter-
lived 
51
Mn
2+
, or the performance of dynamic PET scanning under a 
52
Mn
2+
 infusion regime that allows for 
the deconvolution of the endocrine signal from the exocrine background. 
Aside from VDCC, there are several endogenous mechanisms for Mn
2+
 uptake including 
facilitated diffusion, divalent metal transporter-1 (DMT1), Zrt and Irt-related protein-8 (ZIP-8), 
transferrin receptor (TfR), and ionotropic glutamate receptor Ca
2+
 channels (8). The relative role that 
these alternative pathways play in 
52
Mn
2+
 transport remains unknown, but a lack of impact by nifedipine 
suggests that VDCC may not be a primary transport route in many normal tissues. In this regard, our 
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studies also provided valuable information on the kinetics of the whole-body distribution of 
52
Mn
2+
. 
Besides the pancreas, 
52
Mn
2+
 also accumulated in the liver, heart, kidneys, and salivary gland. Despite the 
significant kidney uptake, no clear sign of renal excretion was observed and most of the 
52
Mn
2+
 clearance 
occurred through the hepatobiliary system. From the analysis of the image-derived dynamic TAC of the 
heart, we estimated a 
52
Mn
2+
 circulation half-life of 10.7 ± 3.5 s following a rapid bolus injection, which 
aligned with previous studies showing an extremely fast (~0.8 min) blood clearance of 
54
Mn in dogs (33). 
Such fast extraction kinetics indicate that compartmental modeling could be used to describe 
52
Mn
2+
 
uptake in a more quantitative manner. A stable residual myocardial uptake was observed after complete 
blood clearance, approximately 1 min after injection. Of note was the marked underestimation of 
myocardial uptake by PET compared to biodistribution results, with an average recovery coefficient of 
0.54. This is an inherent limitation of the PET imaging-based quantification of small volumes such as the 
myocardial wall or adrenal glands, which in mice are affected by significant partial volume effects (34; 
35).   
Several PET tracers have been studied as potential β-cell imaging agents. [
11
C]-
Dihydrotetrabenazine (DTBZ) and the 
18
F-labeled DTBZ analog FP-(+)-DTBZ have been shown to have 
high affinity for the type 2 vesicular acetylcholine transporter (VMAT2), which is expressed on the 
surface of rodent β-cells but appears to be entirely absent from pancreatic exocrine tissue (36-39). 
Unfortunately, primate models have shown very low pancreatic uptake of [
11
C]-DTBZ, which suggests 
that the degree of VMAT2 expression is species-dependent (40-42). More work is needed in quantifying 
human β-cell expression of VMAT2, and how expression density is related to β-cell function. Another 
promising PET approach for monitoring in vivo β-cell mass involves compartmental kinetic analysis of 
[
11
C]5-HTP, a compound used clinically for detection of neuroendocrine tumors (43). This compound has 
shown differential clearance from endocrine vs. exocrine pancreatic tissues based on differences in the 
presence of serotonin biosynthesis machinery, which effect [
11
C]5-HTP retention in endocrine cells. With 
this approach, [
11
C]5-HTP tracer uptake is observed to decrease both longitudinally in patients with type 2 
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diabetes and cross-sectionally in patients with type 1 diabetes when compared with healthy controls (44; 
45). Another category of tracers includes radiolabeled (e.g. 
18
F, 
68
Ga, 
64
Cu, 
111
In) derivatives of exendin-4, 
a glucagon-like protein-1 receptor (GLP-1R) agonist (46-50). Fluorescence microscopy has shown that 
GLP-1R is only located on β-cells within the human pancreas (51), making it an attractive molecular 
imaging target due to its specificity. In animals models, exendin-4-PET suffers from low pancreatic 
uptake relative to the surrounding organs (<0.3 %ID/g in Sprague-Dawley rats at 1 h post-injection 
whereas proximal kidney uptake is >25 %ID/g) (52). Although the kidney uptake of 
52
Mn
2+
 is also 
significant, the pancreatic uptake of 
52
Mn
2+ 
is comparatively high such that improved pancreas-to-
background ratios are attained by 
52
Mn
2+
-PET. In general, the implementation of tracers targeting surface 
receptors of β-cells is extremely challenging, considering the low total mass of β-cells, diffuse pancreatic 
distribution, and heterogeneous receptor expression.  
Aside from following the gain/loss of β-cell mass in pre-diabetic/diabetic patients, there is a 
pressing need for a noninvasive method for longitudinal imaging of β-cell transplants. Islet 
transplantation has been shown to lead to temporary insulin independence in patients with type 1 diabetes 
(53; 54), but has not been widely adopted due to the need for donor tissues. Recent advances in selective 
stem cell differentiation techniques will likely lead to wider clinical adoption of β-cell transplantation 
therapies (55). The ability to noninvasively track the survival and function of transplanted β-cells would 
enable research into the patient-specific efficacy assessment of immune-modulating therapies and the 
development of new therapeutic strategies (56). In this case, the use of 
51
Mn-PET for monitoring islet 
transplant survival is compelling, since it can be performed repeatedly and safely over time.  
In conclusion, the prominent pancreatic uptake, rapid localization kinetics, and well characterized 
metabolic pathways of 
52
Mn
2+
 make it a promising agent for noninvasive PET imaging of functional β-
cell mass, and was corroborated by various post hoc experiments such as histological β-cell mass 
measurements and live-cell imaging of β-cell Ca
2+
 oscillations. With further development, 
51
Mn
2+
 PET 
may also find broad applications in venues ranging from basic research to clinical patient care.  
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Figure Legends 
Figure 1. Tissue distribution and pharmacokinetics of 
52
Mn
2+
. (A) Serial PET images of ICR mice 
injected intravenously with 
52
Mn
2+
 (no anesthesia except during the PET scans). Coronal PET image 
slices were selected to best show pancreatic uptake. Arrows point to: P, pancreas; H, heart; L, liver; I, 
intestines; and SG, salivary gland. (B) ROI-based quantification of 
52
Mn
2+
 uptake in the heart, liver, 
kidneys, muscle, pancreas, and submandibular salivary gland. (C) Ex vivo 
52
Mn
2+
 biodistribution of 
euthanized mice following last time-point PET scans, determined by gamma counting. n = 4. 
Figure 2. Rapid kinetics of tissue 
52
Mn
2+
 uptake revealed by single IV bolus injection or continuous 
IV infusion. Dynamic PET time-activity curves (TACs) derived from hand-drawn ROIs for the pancreas, 
heart/blood, liver, kidneys, salivary gland, and muscle. Blue curves indicate TACs in mice injected with a 
rapid IV bolus of 
52
Mn
2+
, while red curves indicate an IV infusion of 
52
Mn
2+
 over the first 30 min of the 
scans.  
Figure 3. Pharmacological manipulation of VDCC in isolated islets. (A) Cartoon of the β-cell 
triggering pathway. Molecular structures in blue indicate compounds that activate Ca
2+
 influx through 
VDCC, while compounds in red are inhibitory. (B) Uptake of 
52
Mn
2+
 by isolated ob/ob mouse islets. 
Groups of 50 islets from 3 preparations were incubated with 
52
Mn
2+
 (370 kBq) in the presence of glucose 
and VDCC modulators as indicated. Mean ± S.D. *, P < 0.05; **, P < 0.01; ***, P <0.001. 
Figure 4. In vivo assessment of functional β-cell mass by 
52
Mn
2+
-PET. (A) Coronal PET images at 1 h 
post-injection showing the pancreas of ICR mice given IP injections of diazoxide (20 mg/kg), nifedipine 
(20 mg/kg), or glibenclamide (5 mg/kg) prior to the administration of a 
52
Mn
2+
 rapid bolus. The pancreas 
(P) is demarcated by white dashed contours. (B) Manual ROI-based quantification of 
52
Mn
2+ 
uptake in 
various tissues from static PET images acquired at 1 h post-injection. (C) Ex vivo biodistribution analysis 
following PET imaging at 1 h post-injection. Significantly reduced pancreatic uptake of 
52
Mn
2+ 
is 
observed in mice that received nifedipine and diazoxide prior to radiotracer administration. Mice which 
received glibenclamide (5 mg/kg) prior to radiotracer administration had significantly higher pancreatic 
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uptake of 
52
Mn
2+ 
than the control mice, based on both PET imaging (P = 0.02) and biodistribution (P = 
0.047) studies.  Mean ± S.D.; n = 3-4 mice per group. ***, P <0.001.  
Figure 5. 
52
Mn
2+
-PET imaging in streptozotocin (STZ)-induced type 1 diabetes. (A) Following the 
administration of an acute dose of STZ (180 mg/kg), ICR mice started to show symptoms of diabetes: 
reduced body weight and high blood glucose level (BGL; > 250 mg/dL). (B) One-hour post-injection 
coronal PET images of healthy (left panel) or diabetic (center/right panels) ICR mice showing clearly 
reduced PET signal in the pancreas of the STZ-diabetic mice. The significant decline in 
52
Mn
2+
 uptake in 
the pancreas of STZ-diabetic mice was confirmed quantitatively by (C) ROI analysis of the PET images 
and (D) ex vivo biodistribution (n = 3 mice/group). (E) Quantification of β-cell mass for control and STZ-
treated ICR mice. Data are shown as the mean ± S.D.; n = 4 mice per group. *, P < 0.05, ***, P < 0.001.  
Figure 6. 
52
Mn
2+
PET imaging in the ob/ob model of pre-type 2 diabetes. (A) Coronal PET images 
acquired at 1 h after 
52
Mn
2+
 administration in ob/ob mice and C57BL/6J controls. The pancreas (P) is 
demarcated by white dashed contours. (B) Image-derived quantification expressed as SUV indicated a 
significant difference in 
52
Mn
2+
 pancreatic uptake between groups (mean ± S.D; n = 3).  (C) 
Quantification of β-cell mass for wildtype and ob/ob mice. n = 3 mice per group. (D) Recordings of islet 
Ca
2+
 in response to glucose (10 mM and 7 mM) from wildtype and ob/ob C57BL/6J mice. (E) 
Contingency plot showing the range of islet behaviors at each glucose level. (F) The oscillatory plateau 
fraction, reflecting the plasma membrane glucose sensitivity, was calculated as the fraction of time spent 
in the active state during each oscillation at 10 mM glucose. C57BL/6J, n = 141 islets from 4 mice; ob/ob, 
n = 126 islets from 4 mice. Results reflect mean ± S.D. *, P < 0.05, **, P < 0.01, ***, P < 0.001, ****, P 
< 0.0001. 
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Figure 1. Tissue distribution and pharmacokinetics of 52Mn2+. (A) Serial PET images of ICR mice injected 
intravenously with 52Mn2+ (no anesthesia except during the PET scans). Coronal PET image slices were 
selected to best show pancreatic uptake. Arrows point to: P, pancreas; H, heart; L, liver; I, intestines; and 
SG, salivary gland. (B) ROI-based quantification of 52Mn2+ uptake in the heart, liver, kidneys, muscle, 
pancreas, and submandibular salivary gland. (C) Ex vivo 52Mn2+ biodistribution of euthanized mice following 
last time-point PET scans, determined by gamma counting. n = 4.  
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Figure 2. Rapid kinetics of tissue 52Mn2+ uptake revealed by single IV bolus injection or continuous IV 
infusion. Dynamic PET time-activity curves (TACs) derived from hand-drawn ROIs for the pancreas, 
heart/blood, liver, kidneys, salivary gland, and muscle. Blue curves indicate TACs in mice injected with a 
rapid IV bolus of 52Mn2+, while red curves indicate an IV infusion of 52Mn2+ over the first 30 min of the scans. 
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Figure 3. Pharmacological manipulation of VDCC in isolated islets. (A) Cartoon of the β-cell triggering 
pathway. Molecular structures in blue indicate compounds that activate Ca2+ influx through VDCC, while 
compounds in red are inhibitory. (B) Uptake of 52Mn2+ by isolated ob/ob mouse islets. Groups of 50 islets 
from 3 preparations were incubated with 52Mn2+ (370 kBq) in the presence of glucose and VDCC modulators 
as indicated. Mean ± S.D. *, P < 0.05; **, P < 0.01; ***, P <0.001.  
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Figure 4. In vivo assessment of functional β-cell mass by 52Mn2+-PET. (A) Coronal PET images at 1 h post-
injection showing the pancreas of ICR mice given IP injections of diazoxide (20 mg/kg), nifedipine (20 
mg/kg), or glibenclamide (5 mg/kg) prior to the administration of a 52Mn2+ rapid bolus. The pancreas (P) is 
demarcated by white dashed contours. (B) Manual ROI-based quantification of 52Mn2+ uptake in various 
tissues from static PET images acquired at 1 h post-injection. (C) Ex vivo biodistribution analysis following 
PET imaging at 1 h post-injection. Significantly reduced pancreatic uptake of 52Mn2+ is observed in mice that 
received nifedipine and diazoxide prior to radiotracer administration. Mice which received glibenclamide (5 
mg/kg) prior to radiotracer administration had significantly higher pancreatic uptake of 52Mn2+ than the 
control mice, based on both PET imaging (P = 0.02) and biodistribution (P = 0.047) studies.  Mean ± S.D.; 
n = 3-4 mice per group. ***, P <0.001.  
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Figure 5. 52Mn2+-PET imaging in streptozotocin (STZ)-induced type 1 diabetes. (A) Following the 
administration of an acute dose of STZ (180 mg/kg), ICR mice started to show symptoms of diabetes: 
reduced body weight and high blood glucose level (BGL; > 250 mg/dL). (B) One-hour post-injection coronal 
PET images of healthy (left panel) or diabetic (center/right panels) ICR mice showing clearly reduced PET 
signal in the pancreas of the STZ-diabetic mice. The significant decline in 52Mn2+ uptake in the pancreas of 
STZ-diabetic mice was confirmed quantitatively by (C) ROI analysis of the PET images and (D) ex vivo 
biodistribution (n = 3 mice/group). (E) Quantification of β-cell mass for control and STZ-treated ICR mice. 
Data are shown as the mean ± S.D.; n = 4 mice per group. *, P < 0.05, ***, P < 0.001.  
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Figure 6. 52Mn2+-PET imaging in the ob/ob model of pre-type 2 diabetes. (A) Coronal PET images acquired at 
1 h after 52Mn2+ administration in ob/ob mice and C57BL/6J controls. The pancreas (P) is demarcated by 
white dashed contours. (B) Image-derived quantification expressed as SUV indicated a significant difference 
in 52Mn2+ pancreatic uptake between groups (mean ± S.D; n = 3).  (C) Quantification of β-cell mass for 
wildtype and ob/ob mice. n = 3 mice per group. (D) Recordings of islet Ca2+ in response to glucose (10 mM 
and 7 mM) from wildtype and ob/ob C57BL/6J mice. (E) Contingency plot showing the range of islet 
behaviors at each glucose level. (F) The oscillatory plateau fraction, reflecting the plasma membrane glucose 
sensitivity, was calculated as the fraction of time spent in the active state during each oscillation at 10 mM 
glucose. C57BL/6J, n = 141 islets from 4 mice; ob/ob, n = 126 islets from 4 mice. Results reflect mean ± 
S.D. *, P < 0.05, **, P < 0.01, ***, P < 0.001, ****, P < 0.0001.  
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Mice 
All animal experiments were approved by the Institutional Animal Care and Use Committees of the 
University of Wisconsin-Madison and the William S. Middleton Memorial Veterans Hospital. Male ICR 
(Envigo) and C57BL/6J wildtype and ob/ob mice (The Jackson Laboratory) were employed in this work. 
All mice were approximately ten weeks of age at the time of the experiments. Mice had access to food and 
water ad libitum, except under fasting condition when access to food was restricted for 6-12 hours.  
52Mn2+ Production 
52Mn2+ was produced as previously described (1). Production yields of up to 5.92 MBq/µAh (355 MBq/h 
@ 60 µA) were achieved using a chromium pellet pressed into a silver disc substrate. 52Mn2+ was eluted in 
<1mL of 0.01 M NaOAc buffer (pH ~6.5) from a ~150 mg AG 1×8 column which had been conditioned 
with ethanol. As previously described (2), thin layer chromatographs confirmed the Mn2+ oxidation state 
following elution. End of bombardment radionuclidic purity was measured to be >99.5% by efficiency-
calibrated high-purity germanium (HPGe) gamma spectrometry measurements. The only radionuclidic 
impurity observed was <0.5% of 54Mn (t1/2= 312.1 d), which does not decay by positron emission. 
Islet Isolation 
Mouse pancreatic islets were isolated by collagenase digestion as previously reported in (3). Briefly, mice 
were sacrificed via CO2 asphyxiation followed by cervical dislocation. The common bile duct was perfused 
with 4 mL of an ice-cold solution containing type XI collagenase (0.5 mg/mL; Sigma Aldrich) and bovine 
serum albumin (BSA; 0.2 mg/mL; Sigma Aldrich) in Hank’s Balanced Salt Solution (HBSS; Invitrogen). 
After inflation, the pancreas was removed to a glass vial containing 5 mL of collagenase solution, and 
incubated in a shaking water bath at 37°C for approximately 20 min. The digests were centrifuged at 50g 
for 2 min and islet pellets were washed three times with 30 mL ice-cold HBSS/BSA. The pellet was re-
suspended and the islets were handpicked into 35 mm petri dishes. Following isolation, islets were placed 
in RPMI1640 media supplemented with penicillin (100 U/mL; Invitrogen), streptomycin (100 μg/mL; 
Invitrogen), and 10% (wt/vol) FBS (Sigma) and incubated overnight at 37°C in a 5% CO2 atmosphere. 
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Pharmacological Disruption of 52Mn2+ Uptake in Isolated Islets  
Batches of 50 islets were transferred into 0.45 µm-filtered 1 mL centrifuge vials (Thermo Fisher Scientific), 
and incubated with 500 µL of Krebs-Ringer buffer (KRB: 118 mM NaCl, 5.4 mM KCl, 2.4 mM CaCl2, 1.2 
mM MgSO4, 1 mM KH2PO3, 20 mM HEPES; pH 7.4) containing 1 mM glucose for 30 min at 37°C. After 
removing the supernatant by centrifugation at 50g for 5 min, 250 µL of KRB containing 16.7 mM glucose, 
diazoxide (50 μM; Tocris Biosciences), or tolbutamide (250 μM; Selleckchem) were added, and the vials 
were spiked with 370 kBq (10 μCi) of 52Mn2+. After 15 min of incubation, the islets were washed three 
times with KRB. 52Mn2+ radioactivity in the islet pellets was quantified using an automated gamma counter 
(Perkin Elmer). 
Ex vivo 52Mn2+ Biodistribution Analysis 
Ex vivo biodistribution studies were performed in all groups of mice to validate the results of 52Mn2+-PET 
imaging and obtain a more complete profile of tissue 52Mn2+ uptake. Following the last imaging time point, 
mice were euthanized by CO2 asphyxiation and 15 organs of interest were removed, wet-weighed, and 
counted in an automated gamma-counter (Wizard 2480, Perkin Elmer). The tissue uptake of 52Mn2+ was 
reported as SUV (mean ± S.D.). 
Measurement of β-cell Mass 
Similar as our previous report (4), mice were euthanized under anesthesia with CO2 followed by cervical 
dislocation. The pancreas was immediately dissected, weighed, and fixed in 10% formalin on ice for 30 
minutes. Pancreata were then washed in PBS and transferred through a series of solutions, beginning with 
30% sucrose in PBS, 1:1 30% sucrose:OCT, and OCT before cryopreservation in OCT and storage at -
80°C. 10-micron serial sections were cut on positively charged slides, with 9 sections per stop position 
(3/slide) and two stop positions per pancreas separated by at least 200 microns. For each pancreas, one slide 
per position was post-fixed, quenched of peroxidase activity with 3% H2O2, and immunohistochemically 
labeled using guinea pig anti-insulin primary antibody (Dako A056401-2), diluted 1:500 in antibody 
diluent, and co-stained with hematoxylin (Sigma, GHS280). Slides were imaged using an automated pan-
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and-stich microscope at 10× (Evos). β-cell fractional area was determined by quantifying the percent of 
insulin-positive pancreas area as a total of the full pancreas area for each section, followed by averaging of 
2 distinct sections per mouse. Images were analyzed using ImageJ (64-bit) software (National Institutes of 
Health, Bethesda, MD) with shading correction. β-cell mass was calculated by multiplying β-cell fractional 
area by the pancreatic wet weight. 
Islet Ca2+ Imaging 
For measurements of cytosolic Ca2+, islets were pre-incubated in 2.5 µM FuraRed (Molecular Probes) for 
45 min at 37C. Islets were then placed in an RC-41LP glass-bottomed chamber mounted in a QE-1 
platform (Warner Instruments) on a Nikon Ti-Eclipse inverted microscope equipped with a 20×/0.75NA 
SuperFluor objective (Nikon Instruments). The chamber was perfused with standard external solution with 
glucose (in mM: 135 NaCl, 4.8 KCl, 5 CaCl2, 1.2 MgCl2, 20 HEPES; pH 7.35). The flow rate was 0.5 
ml/min and temperature was maintained at 33°C using inline solution and chamber heaters (Warner 
Instruments). Excitation was provided by a SOLA SEII 365 (Lumencor) set to 10% output. Excitation 
(430/20 nm and 500/20 nm) and emission (630/70 nm) filters (ET type, Chroma Technology Corporation) 
were used in combination with an FF444/521/608-Di01 dichroic (Semrock). Fluorescence emission was 
collected with a Hamamatsu ORCA-Flash4.0 V2 Digital CMOS camera at 0.125 Hz. A single region of 
interest was used to quantify the average response of each islet as the excitation ratio (R430/500) using 
Nikon Elements and MathWorks MATLAB software as in (3).  
Statistics 
A minimum sample size of three (n=3) was used in all in vitro and in vivo experiments. The uptake of 
52Mn2+ in the different tissues was reported as SUV (mean ± S.D.) and the differences between groups were 
evaluated for significance using a two-tailed Student’s t-test. Differences were considered statistically 
significant at P < 0.05. 
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 Figure S1 Three-dimensional rendering of the pancreas and kidneys PET signal in ICR mice 
injected a rapid IV 52Mn2+ bolus. Three different view angles are presented showing the separation 
between pancreas and the left kidney. The animal subject shown here is the same displayed in 
Figure 1 of the main text. 
  
Pancreas
Kidneys
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Figure S2. Impact of isoflurane on pancreatic uptake of 52Mn2+ in mice. ICR mice (3-6 per group) 
received either an intravenous bolus of 52Mn2+, or an intraperitoneal injection of glucose (1 mg/kg) 
followed by an intravenous infusion of 52Mn2+ from 5 to 15 minutes following glucose 
administration. A subset of these treatments was anesthetized with 2% isoflurane during injections, 
whereas the rest of the mice were not anesthetized. One hour following 52Mn2+ administration, 
mice were euthanized and ex vivo biodistribution studies were performed via gamma counting. 
Pancreatic uptake of 52Mn2+ was found to be significantly lower in both groups under isoflurane 
anesthesia, when compared to non-anesthetized controls, suggesting that isoflurane prevents 
voltage-dependent calcium channel (VDCC) mediated 52Mn2+ influx.  
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Figure S3 Ex vivo biodistribution of lean (C57BL/6J) and obese (ob/ob) mice, one-hour post 
injection of 52Mn2+. Significantly higher 52Mn2+ uptake can be noted in obese mice compared to 
the lean controls (***P < 0.0001; n=3). 
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Table S1.  Quantitative results of longitudinal PET imaging studies in ICR mice administered a 
52Mn2+ intravenous bolus (n = 4) 
 Organ/tissue uptake 
Time 
(days) 
Heart/blood Liver Kidneys Muscle Pancreas S Gland 
0.042 2.11 ± 0.20 3.27 ± 0.34 5.13 ± 0.02 0.38 ± 0.03 5.13 ± 0.37 2.30 ± 0.26 
0.125 1.88 ± 0.19 3.37 ± 0.47 5.21 ± 0.32 0.38 ± 0.02 5.11 ± 0.50 2.53 ± 0.44 
0.5 1.21 ± 0.16 3.51 ± 0.29 4.90 ± 0.19 0.35 ± 0.05 4.89 ± 0.17 2.77 ± 0.19 
1 0.93± 0.11 3.15 ± 0.28 4.59 ± 0.27 0.33 ± 0.03 4.84 ± 0.18 2.69 ± 0.05 
3 0.80 ± 0.08 1.94 ± 0.17 3.32 ± 0.14 0.27 ± 0.05 4.40 ± 0.34 2.85 ± 0.09 
5 0.72 ± 0.05 1.49 ± 0.05 2.60 ± 0.03 0.26 ± 0.03 3.65 ± 0.37 3.18 ± 0.33 
7 0.69 ± 0.00 1.08 ± 0.10 1.96 ± 0.21 0.20 ± 0.02 2.98 ± 0.25 3.02 ± 0.13 
9 0.64 ± 0.02 0.83 ± 0.06 1.56 ± 0.20 0.18 ± 0.02 2.26 ± 0.23 2.70 ±0.10 
11 0.58 ± 0.03 0.70 ± 0.02 1.28 ± 0.14 0.19 ± 0.01 1.80 ± 0.23 2.63 ± 0.15 
 13 0.54± 0.03 0.62 ± 0.01 1.13 ± 0.06 0.19 ± 0.01 1.65 ± 0.31 2.50 ±0.08 
Mean ± SD values are reported as standardized uptake value (SUV) 
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Table S2. Ex vivo biodistribution of 52Mn2+ at day 13 after intravenous administration in healthy 
ICR mice. n = 4. 
Organ/tissue 52Mn2+ uptake 
(SUV)* 
52Mn2+ uptake 
(%ID/g)* 
Blood 0.01 ± 0.01 0.06 ± 0.02 
Skin 0.16 ± 0.05 0.56 ± 0.18 
Muscle 0.26 ± 0.04 0.93 ± 0.14 
Bone 0.50 ± 0.09 1.78 ± 0.28 
Heart 1.19 ± 0.08 4.25 ± 0.18 
Lung 0.22 ± 0.06 0.80 ± 0.22 
Liver 0.72 ± 0.04 2.57 ± 0.14 
Kidney 1.85 ± 0.04 6.57 ± 0.23 
Spleen 0.35 ± 0.10 1.23 ± 0.34 
Pancreas 2.62 ± 0.44 9.30 ± 1.29 
Stomach 0.76 ± 0.18 2.68 ± 0.61 
Intestine 0.14 ± 0.02 0.49 ± 0.07 
Salivary 2.84 ± 0.13 10.13 ± 0.38 
Tail 0.14 ± 0.01 0.54 ± 0.05 
Brain 0.52 ± 0.01 1.87 ± 0.07 
 *Mean ± SD 
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Table S3. Quantitative results of PET imaging in ICR mice 1 h post administration of 52Mn2+ under 
various conditions to stimulate or inhibit insulin release. 
Organs 
Baseline 
(n=3) 
Diazoxide 
(n=3) 
Nifedipine 
(n=3) 
Glibenclamide 
(n=4) 
STZ-diabetic 
(n=3) 
Heart/blood 2.11 ± 0.20 2.58 ± 0.22 2.61 ± 0.30 2.50 ± 0.60 1.97 ± 0.50 
Liver 3.27 ± 0.34 3.11 ± 0.50 2.06 ± 0.56 3.20 ± 0.87 2.89 ± 1.70 
Kidneys 5.13 ± 0.02 4.66 ± 1.48 3.52 ± 0.43 5.70 ± 1.35 3.80 ± 0.78 
Muscle 0.38 ± 0.03 0.40 ± 0.07 0.44 ± 0.07 0.44 ± 0.04 0.23 ± 0.06 
Pancreas 5.13 ± 0.38 2.85 ± 0.92 2.36 ± 0.61 6.47 ± 1.36 2.04 ± 0.81 
Salivary 
Gland 
2.30 ± 0.26 2.46 ± 0.97 2.15 ± 0.22 2.25 ± 0.14 1.51 ± 1.01 
Mean ± SD values are reported as standardized uptake value (SUV) 
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Table S4. One-hour post injection ex vivo biodistribution data in ICR mice administered 52Mn2+ 
under various conditions to stimulate or inhibit insulin release. 
Organs 
Baseline 
(n=3) 
Diazoxide 
(n=3) 
Nifedipine 
(n=3) 
Glibenclamide 
(n=4 ) 
STZ diabetic 
(n=3) 
Heart 4.01 ± 0.26 4.96 ± 0.46 5.42 ± 0.81 5.29 ± 1.19 1.97 ± 0.50 
Liver 3.63 ± 0.13 3.17 ± 0.83 1.84 ± 0.45 3.26 ± 0.70 2.89 ± 1.70 
Kidneys 8.12 ± 0.88 6.42 ± 2.67 4.55 ± 0.84 8.10 ± 1.22 3.80 ± 0.78 
Spleen 1.74 ± 0.22 1.75 ± 0.47 0.52 ± 0.13 1.68 ± 0.40 0.23 ± 0.06 
Pancreas 6.31 ± 0.51 4.43 ± 1.08 3.20 ± 0.61 7.53 ± 1.29 2.04 ± 0.81 
Intestine 1.96 ± 0.32 2.40 ± 0.99 1.94 ± 0.14 2.25 ± 0.64 1.51 ± 1.01 
Salivary 
Gland 
2.90 ± 0.67 2.97 ± 0.62 2.35 ± 0.16 2.68 ± 0.46 1.97 ± 0.50 
Mean ± SD values are reported as standardized uptake value (SUV) 
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Table S5. In vivo PET and ex vivo biodistribution data in C57BL/6J and obese (ob/ob) mice one-
hour after intravenous administration of 52Mn2+. n = 3. 
 In vivo 
PET Data 
 Ex vivo 
biodistribution 
Organs C57BL/6J 
(n=3) 
Ob/Ob 
(n=3) 
Organs C57BL/6J 
(n=3) 
Ob/Ob 
(n=3) 
Heart/blood 1.93 ± 0.10 3.32 ± 0.13 Heart 3.68 ± 0.15 5.93 ± 0.69 
Liver 3.40 ± 0.73 3.68 ± 0.25 Liver 3.33 ± 0.29 3.63 ± 0.10 
Kidneys 5.08 ± 0.37 9.43 ± 0.44 Kidneys 5.58 ± 0.16 13.94 ± 
1.91 
Muscle 0.38 ± 0.06 0.26 ± 0.09 Spleen 1.74 ± 0.46 2.65 ± 0.27 
Pancreas 4.89 ± 0.68 7.27 ± 1.03 Pancreas 5.19 ± 0.52 9.79 ± 0.83 
Salivary 
Gland 
2.40 ± 0.20 3.11 ± 1.05 Intestine 1.72 ± 0.33 4.17 ± 0.21 
   Salivary 
Gland 
3.18 ± 0.49 4.57 ± 0.95 
Mean ± SD values are reported as standardized uptake value (SUV) 
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Table S6.  Quantitative results of longitudinal PET imaging studies in ICR mice administered a 
52Mn2+ intravenous bolus (n = 4) 
 Organ/tissue uptake 
Time 
(days) 
Heart/blood Liver Kidneys Muscle Pancreas S Gland 
0.042 7.50 ± 0.61 11.63 ± 1.12 18.30 ± 0.53 1.37 ± 0.12 18.30 ± 1.71 8.20 ± 0.92 
0.125 6.70 ± 0.62 12.00 ± 1.41 18.57 ± 1.42 1.37 ± 0.06 18.23 ± 2.21 9.00 ± 1.35 
0.5 4.30 ± 0.61 12.50 ± 0.69 17.47 ± 0.21 1.27 ± 0.15 17.43 ± 0.87 9.87 ± 0.49 
1 3.33 ± 0.42 11.20 ± 0.72 16.33 ±0.72 1.17 ± 0.12 17.23 ± 0.40 9.60 ± 0.30 
3 2.83 ± 0.21 6.90 ± 0.46 11.83 ± 0.45 0.96 ± 0.15 15.70 ± 1.59 10.17 ± 0.38 
5 2.57 ± 0.15 5.30 ± 0.10 9.27 ± 0.25 0.93 ± 0.06 13.03 ± 1.56 11.20 ± 0.85 
7 2.47 ± 0.06 3.83 ± 0.29 7.00 ± 0.87 0.73 ± 0.07 10.63 ± 1.17 10.77 ± 0.71 
9 2.30 ± 0.10 2.93 ± 0.15 5.57 ± 0.84 0.64 ± 0.05 8.07 ± 0.90 9.63 ± 0.32 
11 2.07 ± 0.15 2.50 ± 0.10 4.57 ± 0.61 0.66 ± 0.02 6.43 ± 0.95 9.37 ± 0.55 
 13 1.93 ± 0.06 2.20 ± 0.10 4.03 ± 0.31 0.66 ± 0.05 5.90 ± 1.20 8.90 ± 0.26 
Mean ± SD values are reported as percent injected dose per gram (%ID/g) 
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Table S7. Quantitative results of PET imaging in ICR mice 1 h post administration of 52Mn2+ under 
various conditions to stimulate or inhibit insulin release. 
Organs 
Baseline 
(n=3) 
Diazoxide 
(n=3) 
Nifedipine 
(n=3) 
Glibenclamide 
(n=4) 
STZ-diabetic 
(n=3) 
Heart/blood 7.50±0.61 8.27±1.75 10.93±0.76 8.25±1.68 7.63±1.94 
Liver 11.63±1.12 9.77±0.42 8.53±1.63 10.55±2.39 11.83±8.63 
Kidneys 18.30±0.53 14.53±3.27 14.73±0.99 18.73±2.65 14.80±3.82 
Muscle 1.37±0.12 1.29±0.37 1.83±0.15 1.45±0.10 0.86±0.14 
Pancreas 18.30±1.71 9.03±2.74 9.87±2.42 21.28±2.43 7.70±2.49 
Salivary 
Gland 
8.20±0.92 7.97±3.69 9.03±1.10 7.48±0.29 5.53±3.20 
Mean ± SD values are reported as standardized uptake value (%ID/g) 
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Table S8. One-hour post injection ex vivo biodistribution data in ICR mice administered 52Mn2+ 
under various conditions to stimulate or inhibit insulin release. 
Organs 
Baseline 
(n=3) 
Diazoxide 
(n=3) 
Nifedipine 
(n=3) 
Glibenclamide 
(n=4) 
STZ diabetic 
(n=3) 
Heart 13.10±1.90 15.85±3.02 22.72±3.12 17.46±3.10 15.13±3.33 
Liver 8.01±0.33 9.87±1.62 7.63±1.24 10.79±2.22 15.11±11.18 
Kidneys 30.77±4.67 19.92±6.50 19.04±3.15 26.85±3.34 22.85±6.62 
Spleen 5.85±0.69 5.42±0.94 2.18±0.42 5.52±0.85 3.39±1.36 
Pancreas 21.62±2.49 14.03±3.27 13.33±1.64 24.85±2.05 10.14±3.92 
Intestine 9.23±0.74 7.44±2.56 8.17±0.69 7.55±2.58 8.33±4.19 
Salivary 
Gland 
10.03±1.78 8.81±3.80 9.86±0.83 8.85±0.63 7.11±4.45 
Mean ± SD values are reported as percent injected dose per gram (%ID/g) 
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Table S9. In vivo PET and ex vivo biodistribution data in C57BL/6J and obese (ob/ob) mice one-
hour after intravenous administration of 52Mn2+. n = 3. 
 In vivo 
PET Data 
 Ex vivo 
biodistribution 
Organs C57BL/6J 
(n=3) 
Ob/Ob 
(n=3) 
Organs C57BL/6J 
(n=3) 
Ob/Ob 
(n=3) 
Heart/blood 8.57±0.60 7.33±0.50 Heart 16.36±0.74 13.10±1.90 
Liver 15.07±2.97 8.10±0.36 Liver 14.75±1.01 8.01±0.33 
Kidneys 22.53±1.31 20.80±1.61 Kidneys 24.79±1.13 30.77±4.67 
Muscle 1.70±0.30 0.58±0.20 Spleen 7.72±1.95 5.85±0.69 
Pancreas 21.70±2.86 16.07±2.67 Pancreas 23.03±1.94 21.62±2.49 
Salivary 
Gland 
10.63±0.91 6.80±2.08 
Intestine 
7.62±1.42 9.23±0.74 
   Salivary 
Gland 
14.12±2.35 10.01±1.78 
Mean ± SD values are reported as standardized uptake value (%ID/g) 
 
 
 
  
Page 42 of 43Diabetes
REFERENCES 
 
1. Graves SA, Hernandez R, Fonslet J, England CG, Valdovinos HF, Ellison PA, Barnhart TE, 
Elema DR, Theuer CP, Cai W: Novel Preparation Methods of 52Mn for ImmunoPET Imaging. 
Bioconjug Chem 2015;26:2118-2124 
2. Lewis CM, Graves SA, Hernandez R, Valdovinos HF, Barnhart TE, Cai W, Meyerand ME, 
Nickles RJ, Suzuki M: 52Mn production for PET/MRI tracking of human stem cells expressing 
divalent metal transporter 1 (DMT1). Theranostics 2015;5:227 
3. Gregg T, Poudel C, Schmidt BA, Dhillon RS, Sdao SM, Truchan NA, Baar EL, Fernandez 
LA, Denu JM, Eliceiri KW, Rogers JD, Kimple ME, Lamming DW, Merrins MJ: Pancreatic 
beta-Cells From Mice Offset Age-Associated Mitochondrial Deficiency With Reduced KATP 
Channel Activity. Diabetes 2016;65:2700-2710 
4. Brill AL, Wisinski JA, Cadena MT, Thompson MF, Fenske RJ, Brar HK, Schaid MD, Pasker 
RL, Kimple ME: Synergy Between Galphaz Deficiency and GLP-1 Analog Treatment in 
Preserving Functional beta-Cell Mass in Experimental Diabetes. Mol Endocrinol 2016;30:543-
556 
 
Page 43 of 43 Diabetes
